Diclofenac Cinfa is applied in addressing a range of conditions presenting with systemic or localized discomfort by being relevant for easing symptoms related to inflammatory or irritative states. The medicine is applied across domains where additional symptomatic support is needed, primarily for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. It is also commonly used in clinical scenarios involving acute or episodic changes, providing supportive relief for symptoms related to physical discomfort such as mild-to-moderate general pain, menstrual cramps (dysmenorrhea), and acute migraine headaches.

This therapeutic use contributes to easing the overall symptom burden and supports patients during episodes of heightened discomfort. The medicine is relevant when supportive symptom management is appropriate, and may help patients cope more steadily with symptom fluctuations.

“This supportive assistance may help maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Symptoms related to physical discomfort

Regulatory References

1. NIH MedlinePlus overview of Diclofenac

Who Can and Cannot Use Diclofenac Cinfa? (Official Regulatory Information)

Official regulatory documents define strict criteria for the use of Diclofenac Cinfa. Eligibility is primarily restricted by age, pre-existing health conditions, and specific physiological states.

Absolute Contraindications

Use is absolutely contraindicated in patients with a known Hypersensitivity to Diclofenac or other NSAIDs, including those with Aspirin-sensitive asthma. Prohibited populations include those with active gastrointestinal ulceration, bleeding, or perforation, as well as patients with established Severe Hepatic or Renal Failure. Use is also forbidden in patients with certain Established Cardiovascular Diseases (e.g., NYHA Class II-IV Congestive Heart Failure, Ischaemic Heart Disease, or post-CABG surgery status).

Age and Developmental Status

Population	Eligibility Status	Regulatory Basis
Adults	Permitted for labeled use.	Standard Regulatory Approval
Children under 12	Safety and efficacy not established.	FDA/SmPC Labeling
Last Trimester Pregnancy	Contraindicated.	FDA/SmPC Labeling
Breastfeeding Women	Should not be administered.	SmPC Labeling

Restricted Use and Cautions

Patients with Significant Cardiovascular Risk Factors (e.g., hypertension) or those in the First/Second Trimester of Pregnancy require careful consideration before use. Older adults require caution due to increased risk of serious gastrointestinal events.

Diclofenac Cinfa Interactions with Other Medicines and Products

This section outlines the clinically significant interaction patterns for Diclofenac, the Non-Steroidal Anti-Inflammatory Drug (NSAID) in Diclofenac Cinfa, as documented in official government regulatory information.

---

Official Interaction Classifications and Restrictions

Contraindicated Combinations

Co-administration is officially contraindicated with other systemic NSAIDs (including COX-2 selective inhibitors) due to the risk of additive adverse effects. Use is also prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery and during the third trimester of pregnancy.

Pharmacodynamic Risk Reinforcement

Diclofenac can increase the risk of bleeding or ulceration when taken with Anticoagulants (e.g., Warfarin), Anti-platelet agents, Oral Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs). Concomitant use with Diuretics, ACE Inhibitors, or ARBs may reduce the antihypertensive effect of these medicines and can lead to a documented risk of renal function deterioration, especially in the elderly.

Drug Exposure Alterations

Diclofenac exposure is significantly increased by co-administration with strong CYP enzyme inhibitors such as Voriconazole, an interaction noted in regulatory documents. Conversely, Diclofenac can increase the serum concentrations of co-administered medicines, including Lithium and Digoxin.

Non-Medicinal Substances

Official labeling indicates that the consumption of alcohol increases the documented risk for serious gastrointestinal bleeding.

How Diclofenac Cinfa Works

Diclofenac Cinfa operates by targeting specific enzymatic points within the prostanoid signaling cascade, resulting in defined physiological modulations.

---

Enzymatic Blockade of Prostanoid Synthesis

The primary mechanism involves the reversible inhibition of Cyclooxygenase (COX) enzymes (both COX-1 and COX-2 isoforms). This interaction competitively blocks the active site, preventing the crucial initial step in the arachidonic acid cascade. This action interrupts the entire biosynthetic pathway responsible for generating prostanoids—chemical messengers that govern local tissue responses.

---

Modulation of Nociceptive and Vascular Signaling

The subsequent suppression of Prostaglandin E2 ( PGE2) levels diminishes the chemical sensitization of peripheral nociceptors (pain-sensing nerves), increasing the excitability threshold of these neurons. Furthermore, the reduction of PGE2 modifies local vascular responses, reducing vasodilation and vascular permeability. This same molecular principle extends centrally, where PGE2 inhibition alters the hypothalamic thermoregulation set-point.

---

Mechanistic Scope and Limitations

The mechanism's non-selective nature means that while it effectively targets the inducible COX-2, it also modulates the constitutive COX-1 enzyme. This dual action defines the mechanistic breadth of Diclofenac but also dictates the physiological boundaries of its action, affecting pathways that rely on COX-1 activity (e.g., maintaining gastric mucosal integrity and regulating platelet function).

Official Administration Guidelines

Diclofenac Cinfa is administered across multiple official routes, including oral (tablets, capsules, powder for solution), topical (gel), rectal (suppositories), and parenteral (Intramuscular/Intravenous). The fundamental principle guiding its use is to utilize the lowest effective dosage for the shortest duration necessary to manage symptoms.

Dosing and Frequency

For chronic conditions such as osteoarthritis and rheumatoid arthritis, the standard oral dosage is typically 100 mg to 150 mg per day, administered in divided doses. The maximum recommended oral daily dose for chronic use is generally 150 mg, although specific formulations or acute uses may permit up to 200 mg/day. The dosing frequency typically ranges from once daily (extended-release tablets) to three or four times daily for immediate-release forms.

Administration Specifics

Specific administration requirements govern proper intake. Delayed-release (enteric-coated) tablets must be swallowed whole and must not be crushed or chewed. In contrast, the oral solution powder formulation must be emptied into only 1 to 2 ounces (30-60 mL) of water, mixed, and consumed immediately on an empty stomach.

For parenteral use (injections), administration is typically restricted to a maximum of two days (48 hours) before transitioning to an oral or rectal form. The intravenous route requires the medicine to be diluted and infused over a period of 30 minutes to 2 hours, and it must not be given as a rapid bolus injection. For older adults, the practice is to use the lowest effective dosage for the shortest possible duration.

Research Evidence / Overview of Studies for Diclofenac Cinfa

Evidence for Use in Chronic Joint Conditions

This section will summarize the structure of Randomized Controlled Trials (RCTs) and Systematic Reviews that investigated Diclofenac in research contexts involving symptoms associated with Osteoarthritis and Rheumatoid Arthritis. Research has explored how the medicine was observed in patients with conditions presenting with cycles of stability and flare-ups.

Studies on Osteoarthritis (OA)

Researchers focused primarily on Randomized Controlled Trials (RCTs) to examine the use of Diclofenac in adults and older adults experiencing Osteoarthritis. Outcomes monitored included changes in pain intensity (measured using standardized scales) and assessments of physical function (measured by validated scores). Studies reported measurements of both short-term and mid-term data related to these pain and function scores. However, the evidence for some topical forms is limited concerning the time it takes for a measured response to be observed or the exact duration of the change in pain reporting.

Studies on Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)

The evidence base for these conditions is structured around RCTs (primarily using oral formulations) and comparative reviews that included other treatments as comparators. Outcomes related to systemic or functional imbalance were monitored, including Physician Global Assessment of the disease and tracking changes in specific laboratory markers. The research primarily describes patterns of symptomatic change. There is limited information that specifically addresses whether the medicine influences the long-term progression of the condition itself or structural joint damage.

---

Evidence for Acute Pain and Musculoskeletal Issues

This block will describe the structure of the evidence base supporting short-term use, including single-dose and short-course RCTs that investigated the medicine for symptoms related to acute injuries and primary dysmenorrhea. Outcomes related to episodic or acute changes were assessed, including the time until the first measured change in pain reporting and the use of rescue medication.

Studies observed responses over very short time intervals, ranging from a few hours for single-dose studies up to approximately 14 days for short-course treatments of injuries. Data show patterns related to pain reporting, but findings were mixed across different specific forms of the medicine. Research provides insight into short-term changes, but the follow-up durations were limited to the immediate acute phase.

---

What is Still Uncertain in the Research Landscape

This concluding section will synthesize the main evidence gaps, summarize the areas where research findings have shown inconsistency, and clarify where additional high-quality data are still required. The certainty remains low regarding the extended outcomes of using the medicine for periods beyond the typical follow-up durations. Study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Diclofenac: MedlinePlus Drug Information

Common questions about Diclofenac Cinfa (FAQ)

Q: What is Diclofenac Cinfa and how does it work?

Diclofenac Cinfa is a medicine containing the active substance diclofenac sodium. It belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the production of certain natural substances in the body (prostaglandins) that cause pain, inflammation, and fever.

---

Q: What is Diclofenac Cinfa used for?

Diclofenac Cinfa is used to relieve pain and reduce inflammation in various conditions. These may include:

• Joint pain and swelling, such as in rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis.
• Muscle and bone pain, for example, sprains, strains, back pain, and tendonitis.
• Painful menstrual periods (dysmenorrhea).
• Migraine attacks (in certain formulations).
• Post-operative pain.

The specific conditions treated can vary based on the strength and formulation of the medicine (e.g., tablets, capsules, suppositories, gel).

---

Q: What is the most important information I should know about Diclofenac Cinfa?

As with all NSAIDs, treatment with Diclofenac Cinfa may be associated with an increased risk of serious side effects, particularly with long-term use and high doses. The most important risks include:

• Cardiovascular events, such as heart attack or stroke, especially in people with pre-existing heart conditions or risk factors.
• Gastrointestinal bleeding, ulcers, or perforation of the stomach or intestines, which can be serious and sometimes fatal.

It is important to use the lowest effective dose for the shortest possible duration to minimize these risks. Always discuss your medical history and all current medicines with a doctor before starting treatment.

---

Q: Who should not take Diclofenac Cinfa?

You should not take Diclofenac Cinfa if you have:

• A known allergy to diclofenac, aspirin, ibuprofen, or any other NSAID.
• A history of stomach or intestinal ulcers, bleeding, or perforation related to previous NSAID use.
• An active stomach or duodenal ulcer or bleeding.
• Severe heart failure or established heart disease (e.g., recent heart attack, stroke).
• Severe liver or kidney problems.
• The last three months of pregnancy.

Always inform your doctor about all your medical conditions and medicines before starting Diclofenac Cinfa.

---

Q: What are common side effects of Diclofenac Cinfa?

Common side effects, which affect up to 1 in 10 people, may include:

• Stomach upset (e.g., nausea, vomiting, indigestion, abdominal pain).
• Diarrhea or constipation.
• Headache or dizziness.
• Rash.
• Increases in liver enzymes, detected by blood tests.

If you experience severe stomach pain, black stools, or persistent side effects, you should stop taking the medicine and consult a doctor immediately.

---

Q: Can I take Diclofenac Cinfa if I am pregnant or breastfeeding?

Pregnancy:

• Diclofenac Cinfa should not be taken during the last three months of pregnancy as it can harm the unborn baby.
• During the first six months of pregnancy, it is generally not recommended unless specifically advised by a doctor, who will assess the benefits against the risks.

Breastfeeding:

• Diclofenac passes into breast milk in small amounts.
• Use of the medicine while breastfeeding is generally not recommended.

Always consult your doctor or pharmacist for advice before taking any medicine if you are pregnant, planning to become pregnant, or breastfeeding.

Storage Conditions and Requirements

Diclofenac Cinfa must be stored according to regulatory specifications to ensure product stability. Most formulations, such as tablets, require storage at controlled temperatures, typically not above 25 C or 30 C.

Mandatory handling instructions dictate that the container must be kept tightly closed and the medicine must be protected from light and moisture. Certain topical gels may have an official stability period of 6 months after first opening. All products must be kept out of the sight and reach of children.

Disposal Protocols

Unused or expired medicine must not be disposed of via wastewater or household waste to avoid environmental contamination, as diclofenac poses a risk to aquatic life. Patients are instructed by regulators to ask a pharmacist how to correctly dispose of the medicine or to utilize available drug take-back programs. Disposal must comply with all local regulations.